Ahead Therapeutics is developing a real revolution: a nanotechnology-based technology platform to treat and cure autoimmune diseases.
In the pre-clinical phase, we have demonstrated excellent efficacy and safety in different diseases: Multiple Sclerosis, Type 1 Diabetes, Celiac Disease, Rheumatoid Arthritis and some rare diseases. You may have a family member or someone who suffers from these diseases.
Autoimmune diseases cannot be cured, so today’s treatment is only palliative through chronic drugs with many side effects.
Ahead Therapeutics is developing a paradigm shift: a treatment that changes the course of the disease and is potentially curative, without side effects and inexpensive compared to other therapies.
An autoimmune disease occurs when our immune system mistakenly attacks our tissues. About 4% of the world’s population is affected by autoimmune diseases, of which 70% are women.
The economic potential derived from curing the indicated diseases is unquestionable; This is an aggregate market of “trillions” of euros.
The product (drug) is a PS-liposome that encapsulates the peptide or protein responsible for activating the autoimmune attack. The greatness of our approach is based on “biomimicking”, that is, imitating something that happens billions of times a day to recognize one’s tissues. Precisely, PS-liposomes mimic apoptotic bodies (cells that die in an orderly fashion); When dendritic cells capture the PS-liposome, they think it is an apoptotic body and present the tolerogenic encapsulated peptide to the rest of the cells of the immune system. This REPROGRAMS the immune system and stops the attack and destruction of tissues. The rest of the immune system remains unscathed, unlike when treated with systemic immunosuppressants.
The mechanism of action is safe, robust and transverse. Thanks to “biomimicking”, we do not touch any signalling route. Robust because liposomes interact with all critical cells to reprogram the immune system: T cells, B cells, macrophages and other target cells; In this way, a lasting effect is achieved, avoiding that it has to be a therapy administered chronically; To put it simply, it is like a “reverse vaccine”: tolerance is generated during the first month with two/three administrations of the product, and then a reminder is provided after several months. Cross-sectional because it has been described in all the diseases studied.
Our technology is protected and unique; we have a family of solid patents already granted in different territories.
The business model includes two lines: a) the development of the first product in-house and b) the establishment of collaboration or sublicense agreements with pharmaceutical companies to develop the other indications.
The immediate goal is to bring to the clinic the first product (leading asset) to validate the technology in humans. For several technical and strategic reasons, we have selected an orphan disease – Myasthenia Gravis. The success of this first project will be followed by the developing of the rest of the products in the pipeline: Multiple Sclerosis; Diabetes, Type 1; Celiac Disease and Rheumatoid Arthritis.
In addition to scientific work, we have established relationships with several of the most important pharmaceutical companies under confidentiality agreements with some of them. We hope to close a deal in a few months.
Since the beginning of the project, we have paid a lot of attention to product development (CMC): we have already signed a contract with a CDMO company (Recipharm) to manufacture our product under GMP conditions.
We have also developed and qualified all analytical methods discussed by regulatory agencies. In addition, we have two projects underway to encapsulate multi antigens: this will give us a differential since we will be able to treat complex autoimmune diseases with better guarantees of success.
We have an excellent, mature technical and scientific team with all the necessary profiles to lead the project to success. In addition, we have articulated a collaboration network with KOL and reference research institutions that have validated our technology and actively contributed to generating results.
With your support, we can improve the quality of life of millions of patients suffering from autoimmune diseases and generate economic value and a high return for members.
